A notable example is pembrolizumab, a medication that targets the PD-1 checkpoint and is approved for the treatment of various types of cancer, including melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, and others. Here, PDCD1 is linked to melanoma.